DaVita Inc.
DVA
Clasificación en acciones
#1790
DaVita Inc. specializes in delivering essential kidney dialysis treatments and... DaVita Inc. specializes in delivering essential kidney dialysis treatments and comprehensive renal care to individuals grappling with chronic kidney failure. The company primarily operates an extensive network of outpatient dialysis centers, supplementing this with services provided in hospital inpatient settings and within patients' homes. Beyond direct patient treatment, DaVita manages its own diagnostic laboratories, performing routine tests vital for dialysis patients, alongside other physician-ordered laboratory analyses specifically for those with end-stage renal disease (ESRD). The firm also offers administrative and management support to various other outpatient dialysis facilities. Its broad spectrum of offerings extends to chronic disease management programs, supporting a substantial patient cohort; by year-end 2021, this included 16,000 patients enrolled in risk-based integrated care models and an additional 7,000 in other integrated care arrangements. Further specialized services encompass vascular access interventions, clinical research initiatives, direct physician support, and a complete suite of holistic kidney care solutions. As of December 31, 2021, DaVita's footprint across the United States comprised 2,815 outpatient dialysis centers, collectively serving approximately 203,100 patients. Globally, the company operated 339 outpatient dialysis centers spread across ten countries outside the U.S., attending to roughly 39,900 patients. Moreover, it furnished acute inpatient dialysis services and related laboratory work in around 850 U.S. hospitals. Founded in 1994, DaVita Inc. maintains its headquarters in Denver, Colorado. The company rebranded to its current name in September 2016, having previously been known as DaVita HealthCare Partners Inc.
Precio por acción
$187.20
Última sincronización: 2026-10-19
Capitalización bursátil
$11.94B
Cambio (1 día)
0.21%
Cambio (1 año)
46.19%
País
US
Comercio DaVita Inc. (DVA)
Categoría
Healthcare
Ratio P/E de DaVita Inc. (DVA)
Ratio P/E al October 2026 TTM: 15.54
Según los últimos informes financieros y el precio de las acciones de DaVita Inc., el P/E actual (TTM) de la empresa es 15.54. Al final de 2024, la empresa tenía un P/E de 13.57.
Historial del ratio P/E de DaVita Inc. desde 2000 hasta 2026
Relación P/E al final de cada año
| Año | Ratio P/E | Cambiar |
|---|---|---|
| 2026 (TTM) | 15.54 | 15.69% |
| 2025 | 13.43 | -1.10% |
| 2024 | 13.57 | -1.30% |
| 2023 | 13.75 | 11.00% |
| 2022 | 12.39 | 1.28% |
| 2021 | 12.23 | -32.70% |
| 2020 | 18.18 | 28.28% |
| 2019 | 14.17 | -74.30% |
| 2018 | 55.14 | 168.49% |
| 2017 | 20.54 | 39.58% |
| 2016 | 14.71 | -73.13% |
| 2015 | 54.76 | 146.24% |
| 2014 | 22.24 | 5.88% |
| 2013 | 21.00 | 6.08% |
| 2012 | 19.80 | 31.89% |
| 2011 | 15.01 | -13.66% |
| 2010 | 17.39 | 20.76% |
| 2009 | 14.40 | 3.35% |
| 2008 | 13.93 | -10.87% |
| 2007 | 15.63 | -23.10% |
| 2006 | 20.33 | -8.92% |
| 2005 | 22.32 | 27.09% |
| 2004 | 17.56 | 25.84% |
| 2003 | 13.95 | 23.89% |
| 2002 | 11.26 | -24.48% |
| 2001 | 14.92 | -85.60% |
| 2000 | 103.60 | 0.00% |
Relación P/E para empresas similares o competidores
| Empresa | P/E Ratio | Diferencia del P/E Ratio | País |
|---|---|---|---|
| 15.70 | 1.06% |
US
|
|
| - | - |
DE
|
|
| 10.40 | -33.08% |
US
|
|
| 32.07 | 106.40% |
SA
|
|
| 20.00 | 28.72% |
BR
|
¿Cómo leer un P/E ratio?
El ratio Precio/Beneficio (P/E Ratio) mide la relación entre el precio de las acciones de una empresa y sus beneficios por acción.
Un P/E bajo pero positivo indica una empresa con altos beneficios en relación a su valoración actual y que podría estar infravalorada. Una empresa con un P/E negativo alto (cerca de 0) indica fuertes pérdidas en comparación con su valoración.
Las empresas con un P/E superior a 30 o negativo suelen considerarse "acciones de crecimiento", lo que significa que los inversores esperan que crezca o se vuelva rentable en el futuro.
Las empresas con un P/E positivo inferior a 10 suelen considerarse "acciones de valor", lo que significa que ya son muy rentables y no se espera un fuerte crecimiento.